SBIR/STTR Research Award

Topical negative pressure dressings for the prevention of chronic wound biofilm

Award identifier 237bedac366e23e40eba3660b1f04f27dac645cd7ee190452847590a9542ebf2Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$316,996

Program and phase

SBIR · Phase I

Award year

2009

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
AFFINERGY, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
YJQ6K1QMS488
Solicitation number
PHS2009-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Chronic wounds are a significant public-health problem, imposing a high cost on society and presenting patients with significant quality of life limitations. A large proportion of patients with chronic wounds, such as diabetic foot ulcers, and venous leg ulcers, are unresponsive to conventional treatment, such as moist dressings. The complications and cost associated with unresponsive ulcers has prompted extensive research, and promising breakthroughs toward improved chronic wound care. Technologies like antimicrobial silver, topical growth factors and ultrasound have all contributed to the current state of care. The use of topical negative pressure (TNP) dressings has grown in popularity and is now a mainstream treatment for both surgical wounds and chronic wounds. The therapeutic mechanism for improved healing brought on by TNP dressings is thought to be rooted in several properties. Increased blood flow, reduced edema, and the physical removal of enzymes from the wound bed are all thought to contribute to healing. Despite these putative accelerators of healing, the presence of bacteria and subsequent formation of biofilm within the wound during the application of negative pressure remains a common inhibitor of wound healing. Therefore, chemical or mechanical debridement, removing necrotic tissue and biofilm itself, represents an essential first step toward returning the wounded tissue to a normal state of healing. Instead of any one species of bacteria, most chronic wound biofilms are comprised of multiple species. Any treatment intended to accelerate healing by clearing or killing these infections must therefore have broad antimicrobial activity against the most commonly reported species in the chronic wound clinical literature: Staphylococcus aureus and Pseudomonas aeruginosa. We propose here, the development of a peptide-based delivery system that links antibiotics to the polyurethane sponge used to apply topical negative pressure to wounds. Based on the porous structure of the sponges, and their implantation into the debrided wound site, these materials provide an excellent surface from which to deliver bactericidal doses of antibiotics, thereby providing continued protection against recurrent biofilm. We have identified tobramycin (strongly active against Pseudomonas aeruginosa and Gram positive bacteria) as the clinically preferred agent for this application. Coupling the powerful technology of topical negative pressure with improved biofilm prevention using local antibiotics could provide a unique combination tailored specifically toward the clinical situation found in soft tissue wounds. PUBLIC HEALTH RELEVANCE: The research program proposed here is designed to initiate the development of a local antimicrobial delivery system for the treatment and prevention of biofilm in acute and chronic wounds in combination with topical negative pressure wound dressings. The impact of the proposed product concept on patients, physicians and the state of care would promote enhanced quality of life and potentially a reduction in extended medical care precipitated by complicated wounds.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

75 SBIR/STTR records share this UEI (2005–2023). Reported award amounts total $59,804,968. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.